Tirzepatide 20 mg (VLS)

High‑Potency GIP + GLP‑1 Dual‑Agonist Injection for Advanced Appetite Control & Accelerated Fat‑Loss Results

Tirzepatide 20 mg (VLS) delivers a powerful dual‑agonist formulation activating both GIP and GLP‑1 receptors, replicating the mechanism behind the clinical success of Mounjaro. This high‑strength version is engineered for users seeking maximum appetite suppression, enhanced metabolic efficiency, and rapid weekly fat‑loss progression.

The 20 mg strength sits at the upper‑premium tier of Tirzepatide formulations, offering deeper metabolic activation and stronger craving control than standard therapeutic doses.

Key Features

• High‑potency 20 mg Tirzepatide formulation
• Dual‑agonist mechanism: GIP + GLP‑1
• Strong appetite suppression and craving reduction
• Enhances insulin sensitivity and glycemic balance
• Accelerates fat oxidation and metabolic rate
• Supports rapid, visible fat‑loss progression
• Once‑weekly injectable format
• Inspired by the clinical performance of Mounjaro

How Tirzepatide 20 mg (VLS) Works

GLP‑1 Activation

• Reduces appetite
• Slows gastric emptying
• Enhances satiety

GIP Activation

• Improves insulin response
• Supports metabolic stability
• Enhances tolerability

Together, these pathways create synergistic metabolic acceleration, delivering stronger fat‑loss results than GLP‑1‑only therapies.

Benefits

• Strong appetite and craving control
• Faster fat‑loss progression
• Improved glycemic balance
• Increased metabolic rate
• Once‑weekly convenience
• Ideal for intermediate to advanced users

Who It’s For

The Tirzepatide 20 mg (VLS) formulation is suited for:

• Users progressing from lower‑dose Tirzepatide
• Individuals requiring stronger appetite suppression
• Those targeting accelerated fat‑loss performance
• Users familiar with GLP‑1 or dual‑agonist therapies

Safety Information

Commonly reported effects:

• Mild nausea
• GI discomfort
• Fatigue

Not suitable for:

• Pregnant or breastfeeding individuals
• Patients with personal/family history of medullary thyroid carcinoma
• Individuals with MEN2 syndrome

This product is not an approved pharmaceutical and is intended for research or professional use